Polyol sweetners and cardiovascular and thrombotic event risk

A method of detecting the level of erythritol in a biological sample that also contains erythritol's structural isomer threitol, comprising:

• a) mixing a biological sample from a subject with at least one stable isotope labeled structural isomer (SIL isomer) family member selected from:
• stable isotope labelled erythritol (SIL-erythritol) and SIL-threitol,
• b) mixing said biological sample with a hydroxyl group modifying agent such that said SIL isomer and erythritol and any threitol present in said biological sample are modified, thereby generating modified-erythritol, modified-threitol, and modified SIL isomer;
• c) subjecting said biological sample to purification such that said modified-erythritol, modified-threitol, and said modified SIL isomer are substantially isolated from other components of said biological sample, thereby generating a purified sample;
• and
• d) subjecting said purified sample to mass spectrometry such that peak intensity values are generated for said modified-erythritol, modified-threitol, and said modified SIL isomer;
• and
• e) employing the peak intensity value of said modified SIL isomer as an internal standard, and the peak intensity of said modified-erythritol, to determine the level of said erythritol present in said biological sample.

A method comprising:

• a) receiving results of, or conducting, a circulating polyol sweetener analysis on a biological sample from a subject with, or suspected of having, or at increased risk of developing:
• a cardiovascular disease, a major adverse cardiovascular event, or enhanced thrombosis;
• and
• b) performing at least one of the following after identifying said biological sample as having higher levels of said polyol sweetener compared to control levels,
• i) treating said subject with a CVD therapeutic, anti-coagulating agent, anti-platelet agent;
• ii) treating said subject with lipid lowering agents, or BP control agent or therapy;
• iii) treating said subject with antiplatelet agents, due to the increased thrombosis risks associated with elevated polyol sweetener,
• iv) prescribing, or administering, to said subject a dietary intervention to reduce polyol sweetener levels in their diet;
• v) treating said subject with heart failure related therapy efforts;
• and/or
• vi) transmitting a report to said subject or medical personnel treating said subject, indicating said subject is suitable for, or should be, treated with any of i)-v) above.

A kit or system or composition comprising:

• a) at least one stable isotope labeled structural isomer (SIL isomer) family member selected from:
• stable isotope labelled xylitol (SIL-xylitol), SIL-arabitol, and SIL-rabitol;
• and
• b) at least one of the following:
• i) a mass spectrometer,
• ii) a hydroxyl group modifying agent;
• iii) a biological sample from a subject, optionally wherein the subject with, or suspected of having, or at increased risk of developing:
• a cardiovascular disease, a major adverse cardiovascular event, or enhanced thrombosis.

A kit or system or composition comprising:

• a) at least one stable isotope labeled structural isomer (SIL isomer) family member selected from:
• stable isotope labelled erythritol (SIL-erythritol) and SIL-threitol;
• and
• b) at least one of the following:
• i) a mass spectrometer,
• ii) hydroxyl group modifying agent;
• iii) a biological sample from a subject, optionally wherein the subject with, or suspected of having, or at increased risk of developing:
• a cardiovascular disease, a major adverse cardiovascular event, or enhanced thrombosis.